Results 71 to 80 of about 16,069 (248)

Hippo/Mst signaling coordinates cellular quiescence with terminal maturation in iNKT cell development and fate decisions [PDF]

J Exp Med, 2020
Jana Raynor, Chaohong Liu, Yogesh Dhungana, Cliff Guy, Nicole M. Chapman, Hao Shi, Geoffrey Neale, Hiromi Sesaki, Hongbo Chi   +8 more
openalex   +3 more sources

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease [PDF]

PLOS ONE, 2017
Invariant NKT (iNKT) cells can be activated to stimulate a broad inflammatory response. In murine models of sickle cell disease (SCD), interruption of iNKT cell activity prevents tissue injury from vaso-occlusion. NKTT120 is an anti-iNKT cell monoclonal antibody that has the potential to rapidly and specifically deplete iNKT cells and, potentially ...
Joshua J. Field, Elaine Majerus, Kenneth I. Ataga, Elliot P. Vichinsky, Robert Schaub, Robert Mashal, David G. Nathan   +6 more
openaire   +5 more sources

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells

Stem Cell Research & Therapy
Invariant natural killer T (iNKT) cells, upon activation, exhibit antitumor roles by bridging innate and acquired immunity. To overcome the challenges in producing iNKT cells from patients with cancer, we previously developed allogeneic human induced ...
Takahiro Aoki, Midori Kobayashi, Momoko Okoshi, Munechika Yamaguchi, Hiroko Okura, Satoko Sasaki, Yoshie Sasako, Sachiko Kira, Yun-Hsuan Chang, Nayuta Yakushiji-Kaminatsui, Jafar Sharif, Masashi Matsuda, Masahiro Kiuchi, Kiyoshi Hirahara, Motoko Y. Kimura, Shinichiro Motohashi, Haruhiko Koseki   +16 more
doaj   +1 more source

iNKT cell regulation of B cell activation in inflammation [PDF]

, 2016
The ability to combat infections through the generation of specific immune responses is critical to our survival. The immune system can react to and combat virtually any molecule presented to it, including those derived from our own body.
Landgraff Hägglöf, Thomas
core   +1 more source

MAIT Cells Suppress IgE‐Mediated Asthma via IFNγ‐Dependent B Cell Regulation

Allergy, EarlyView.
In this study, we demonstrate that MAIT cell antagonism during sensitization and challenge with HDM worsens the development of airway hyperreactivity without effects on type 2 or 17 associated cytokine production or lung inflammation. Rather, MAIT cells appear to regulate HDM‐induced asthma through direct inhibition of IgE production.
Angela M. Cannata, Jaclyn W. McAlees, Julie M. Hargis, Archana Shankar, Shouxiong Huang, Senad Divanovic, Ian P. Lewkowich   +6 more
wiley   +1 more source

iNKT Cell Emigration out of the Lung Vasculature Requires Neutrophils and Monocyte-Derived Dendritic Cells in Inflammation

Cell Reports, 2016
iNKT cells are a subset of innate T cells that recognize glycolipids presented on CD1d molecules and protect against bacterial infections, including S. pneumoniae.
Ajitha Thanabalasuriar, Arpan S. Neupane, Jing Wang, Matthew F. Krummel, Paul Kubes   +4 more
doaj   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

The response of CD1d-restricted invariant NKT cells to microbial pathogens and their products

Frontiers in Immunology, 2015
Invariant natural killer T (iNKT) cells become activated during a wide variety of infections. This includes organisms lacking cognate CD1d-binding glycolipid antigens recognized by the semi-invariant T cell receptor of iNKT cells. Additional studies have
Luc eVan Kaer, Vrajesh eParekh, Lan eWu
doaj   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source